{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intranasal+Ketamine&page=3",
    "query": {
      "intervention": "Intranasal Ketamine",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 62,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intranasal+Ketamine&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intranasal+Ketamine&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T00:26:29.533Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01998958",
      "title": "A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Treatment Resistant Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Esketamine 14 mg",
          "type": "DRUG"
        },
        {
          "name": "Esketamine 28 mg",
          "type": "DRUG"
        },
        {
          "name": "Esketamine 56 mg",
          "type": "DRUG"
        },
        {
          "name": "Esketamine 84 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "20 Years to 64 Years"
      },
      "enrollment_count": 108,
      "start_date": "2014-01-27",
      "completion_date": "2015-09-25",
      "has_results": true,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-10-02T00:26:29.533Z",
      "location_count": 14,
      "location_summary": "Birmingham, Alabama • Garden Grove, California • Hartford, Connecticut + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01998958"
    },
    {
      "nct_id": "NCT04856124",
      "title": "Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Treatment Resistant Depression"
      ],
      "interventions": [
        {
          "name": "Intranasal esketamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Psych Atlanta",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2018-09-01",
      "completion_date": "2021-03-01",
      "has_results": false,
      "last_update_posted_date": "2021-04-23",
      "last_synced_at": "2026-10-02T00:26:29.533Z",
      "location_count": 1,
      "location_summary": "Marietta, Georgia",
      "locations": [
        {
          "city": "Marietta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04856124"
    },
    {
      "nct_id": "NCT01980303",
      "title": "A Study to Assess the Pharmacokinetics of Intranasally Administered Esketamine in Healthy Japanese and Caucasian Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Esketamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "20 Years to 55 Years"
      },
      "enrollment_count": 29,
      "start_date": "2013-11",
      "completion_date": "2014-01",
      "has_results": false,
      "last_update_posted_date": "2014-01-28",
      "last_synced_at": "2026-10-02T00:26:29.533Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01980303"
    },
    {
      "nct_id": "NCT06795659",
      "title": "Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Post Traumatic Stress Disorder PTSD"
      ],
      "interventions": [
        {
          "name": "Esketamine (Intranasal Spray)",
          "type": "DRUG"
        },
        {
          "name": "Massed Prolonged Exposure (PE)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 4,
      "start_date": "2025-06-09",
      "completion_date": "2026-01-16",
      "has_results": false,
      "last_update_posted_date": "2026-01-28",
      "last_synced_at": "2026-10-02T00:26:29.533Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06795659"
    },
    {
      "nct_id": "NCT03043430",
      "title": "Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Anxiety",
        "Pediatric ALL",
        "Procedural Anxiety"
      ],
      "interventions": [
        {
          "name": "Ketamine 100 MG/ML",
          "type": "DRUG"
        },
        {
          "name": "Midazolam 5 MG/ML",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brooke Army Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "2 Years to 12 Years"
      },
      "enrollment_count": 10,
      "start_date": "2016-05",
      "completion_date": "2023-04",
      "has_results": false,
      "last_update_posted_date": "2023-04-25",
      "last_synced_at": "2026-10-02T00:26:29.533Z",
      "location_count": 1,
      "location_summary": "Fort Sam Houston, Texas",
      "locations": [
        {
          "city": "Fort Sam Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03043430"
    },
    {
      "nct_id": "NCT02183272",
      "title": "Emergency Ketamine Treatment of Suicidal Ideation",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Depression",
        "Suicidal Ideation",
        "Suicidal Impulses"
      ],
      "interventions": [
        {
          "name": "Intranasal Ketamine",
          "type": "DRUG"
        },
        {
          "name": "Intranasal Saline Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2016-08",
      "completion_date": "2018-07",
      "has_results": false,
      "last_update_posted_date": "2016-08-05",
      "last_synced_at": "2026-10-02T00:26:29.533Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02183272"
    },
    {
      "nct_id": "NCT05554627",
      "title": "VA Aripiprazole vs Esketamine for Treatment Resistant Depression",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Depressive Disorder, Major"
      ],
      "interventions": [
        {
          "name": "Esketamine",
          "type": "DRUG"
        },
        {
          "name": "Aripiprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 0,
      "start_date": "2023-10-27",
      "completion_date": "2023-10-27",
      "has_results": false,
      "last_update_posted_date": "2024-01-05",
      "last_synced_at": "2026-10-02T00:26:29.533Z",
      "location_count": 26,
      "location_summary": "Tuscaloosa, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more",
      "locations": [
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05554627"
    },
    {
      "nct_id": "NCT02611921",
      "title": "Study of Intranasal Ketamine for Social Impairment in Autism Spectrum Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Autism Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Ketamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "12 Years to 30 Years"
      },
      "enrollment_count": 21,
      "start_date": "2015-12-22",
      "completion_date": "2018-05-07",
      "has_results": false,
      "last_update_posted_date": "2018-10-12",
      "last_synced_at": "2026-10-02T00:26:29.533Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02611921"
    },
    {
      "nct_id": "NCT03185819",
      "title": "Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Depressive Disorder, Major"
      ],
      "interventions": [
        {
          "name": "Intranasal Placebo",
          "type": "DRUG"
        },
        {
          "name": "Midazolam Placebo Solution",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Esketamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "9 Years to 17 Years"
      },
      "enrollment_count": 147,
      "start_date": "2017-10-05",
      "completion_date": "2023-03-31",
      "has_results": true,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-10-02T00:26:29.533Z",
      "location_count": 18,
      "location_summary": "Hartford, Connecticut • New Haven, Connecticut • Atlanta, Georgia + 15 more",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Winfield",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03185819"
    },
    {
      "nct_id": "NCT00492388",
      "title": "Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pain",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "PMI-150 (intranasal ketamine)",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hospira, now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2007-06",
      "completion_date": "2011-08",
      "has_results": false,
      "last_update_posted_date": "2012-01-11",
      "last_synced_at": "2026-10-02T00:26:29.533Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00492388"
    }
  ]
}